Sacramento、CAにおける急性骨髄性白血病の臨床試験

Sacramentoとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する12件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

被験者募集中第2相

Kaiser Permanente Downtown Commons, Sacramento
University of California Davis Comprehensive Cancer Center, Sacramento
Kaiser Permanente-South Sacramento, Sacramento

18歳以上 · 全性別 · 2026/10/05更新 · NCT05564390

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

被験者募集中第2相

University of California Davis Comprehensive Cancer Center, Sacramento

18歳以上 · 全性別 · 2026/10/02更新 · NCT07304011

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

被験者募集中観察研究健康なボランティア歓迎

Mercy Cancer Center - Sacramento, Sacramento
Woodland Memorial Hospital, Woodland · 16マイル先

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

被験者募集中第1相

UC Davis, Sacramento

12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

被験者募集中第2相

University of California Davis Comprehensive Cancer Center, Sacramento

18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

被験者募集中第2相

Kaiser Permanente Downtown Commons, Sacramento
University of California Davis Comprehensive Cancer Center, Sacramento
Kaiser Permanente-South Sacramento, Sacramento

18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

被験者募集中第3相

University of California Davis Comprehensive Cancer Center, Sacramento

6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

被験者募集中第1相

University of California, Davis Comprehensive Cancer Center, Sacramento

18歳〜85歳 · 全性別 · 2026/08/26更新 · NCT06834282

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

被験者募集中観察研究

Sutter Medical Center, Sacramento

全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

被験者募集中第2相

University of California Davis Health (UC Davis Health), Sacramento

18歳以上 · 全性別 · 2026/01/05更新 · NCT05184842

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

被験者募集中第1/2相

University of California, Davis, Sacramento

18歳以上 · 全性別 · 2025/08/26更新 · NCT03850574

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

被験者募集中第2相

University of California Davis Comprehensive Cancer Center, Sacramento

18歳以上 · 全性別 · 2024/05/29更新 · NCT04905810

他の都市における急性骨髄性白血病の試験

Sacramentoにおける他の研究

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。